adimlecleucel (ATA230) / Atara - LARVOL DELTA

Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - P2 | N=78 | Completed | Sponsor: Memorial Sloan Kettering Cancer Center | Recruiting ➔ Completed | N=41 ➔ 78 | Trial completion date: Jun 2024 ➔ Feb 2024 | Trial primary completion date: Jun 2024 ➔ Feb 2024

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Bone Marrow Transplantation • Cytomegalovirus Infection • Infectious Disease • Transplantation

Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - P2 | N=41 | Recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Trial completion date: Jun 2022 ➔ Jun 2024 | Trial primary completion date: Jun 2022 ➔ Jun 2024

Trial completion date • Trial primary completion date • Bone Marrow Transplantation • Cytomegalovirus Infection • Infectious Disease • Transplantation

Dominant epitopes presented by prevalent HLA alleles permit wide use of banked CMVpp65 T-cells in adoptive therapy. (PubMed, Blood Adv) - "However, immunodominant CMVpp65 CTL responding to epitopes presented by certain HLA B*35 alleles were ineffective in lysing CMV infected cells in vitro or controlling CMV infections post adoptive therapy. Analysis of the hierarchy of T-cell responses to CMVpp65, the HLA alleles presenting immunodominant CMVpp65 epitopes, and the responses they induce, may lead to detailed algorithms for optimal choice of 3rd party CMVpp65CTLs for effective adoptive therapy."

Journal • Cytomegalovirus Infection • Infectious Disease • Transplantation • CD4 • CD8

Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - P2; N=41; Recruiting; Sponsor: Memorial Sloan Kettering Cancer Center; Trial completion date: Jun 2021 ➔ Jun 2022; Trial primary completion date: Jun 2021 ➔ Jun 2022

Trial completion date • Trial primary completion date • Bone Marrow Transplantation • Cytomegalovirus Infection • Infectious Disease • Transplantation